Eli Lilly and Company (NYSE:LLY) Shares Sold by Financial Architects Inc
Financial Architects Inc reduced its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% during the second quarter, Holdings Channel reports. The institutional investor owned 1,246 shares of the company’s stock after selling 84 shares during the period. Financial Architects Inc’s holdings in Eli Lilly and were worth $103,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the company. First Command Financial Services Inc. increased its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co acquired a new stake in shares of Eli Lilly and during the first quarter valued at about $135,000. Point72 Asia Hong Kong Ltd increased its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC increased its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Finally, American National Bank increased its stake in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares in the last quarter. 75.59% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE:LLY) traded up 0.35% during mid-day trading on Monday, reaching $81.43. The company’s stock had a trading volume of 851,937 shares. The stock has a market cap of $85.91 billion, a PE ratio of 35.24 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The company has a 50 day moving average of $82.91 and a 200-day moving average of $81.72.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 earnings per share. Equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
Several equities research analysts recently issued reports on the company. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC increased their price objective on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reissued a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank reissued a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the transaction, the insider now directly owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.